



## **Verdiva Bio attending American Diabetes Association 85<sup>th</sup> Scientific Sessions**

**LONDON AND SAN FRANCISCO – 4 June, 2025** – Verdiva Bio Limited (“Verdiva Bio” or “the Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and cardiometabolic disorders, will be participating in the American Diabetes Association (ADA) 85<sup>th</sup> Scientific Sessions in Chicago, US from 20-23 June.

The team will be presenting clinical and pre-clinical data from multiple programs, and meeting with potential partners, collaborators and investors. Further details about the presentations will be released at the meeting.

### **Contact Information**

#### **Verdiva Bio**

Mohamed Eid, CMO

Charlotte Davison, Chief of Staff

info@verdivabio.com

#### **Vigo Consulting (Media)**

Melanie Toyne-Sewell

Rozi Morris

+44 20 7390 0230

VerdivaBio@VigoConsulting.com

### **About Verdiva Bio**

Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the potential viability of once-weekly dosing. The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide.

For more information, please visit [www.verdivabio.com](http://www.verdivabio.com).